Back to results
US 2019/0161513 A1Published application
Synthesis of thiolated oligonucleotides without a capping step
AssigneeBiogen MA Inc.
InventorsXianglin Shi, Jimin Yang, William F. Kiesman, Yannick Fillon
Life of this patent
Estimating the term…
Abstract
The invention herein describes a synthetic method for preparing thiolated oligonucleotides without needing a capping step, as the sulfurization agent caps the unreacted 5′-OH groups.
Claims44
A process for of preparing an oligonucleotide comprising
- a) reacting the compound of Formula (I):
- with the compound of Formula (II):
- to form a compound of Formula (III):
- and
- b) sulfurizing the compound of Formula (III) with a sulfurization agent to form a compound of Formula (IV):
- and from unreacted compound of Formula (I) forms a compound of Formula (V):
- wherein
- Each R1 and R11 are independently a nucleobase, wherein the NH2 of the nucleobase, if present, is protected by an amine protecting group;
- Each R2 and R12 are independently selected from the group consisting of H, halo, and C1-6alkoxy optionally substituted with C1-6alkoxy;
- R3 is a solid support, optionally comprising a linker;
- Y is absent, a nucleotide, or an oligonucleotide comprising 2 or more nucleotides;
- Each R4 is independently H or forms a ring with the alkoxy group of R2;
- Each R14 is independently H or forms a ring with the alkoxy group of R12;
- R15 is a hydroxy protecting group;
- R16 is C1-6alkyl optionally substituted with —CN;
- R17a and R17b are independently C1-6alkyl;
- RS is a hydroxy protecting group formed from a byproduct of the sulfurization agent;
- wherein the sulfurization agent is reacted for a sufficient amount of time to substantially completely convert unreacted compound of Formula (I) to the compound of Formula (V) and to convert the compound of Formula (III) to Formula (IV);
- wherein a sufficient amount of sulfurization agent is added to substantially completely convert unreacted compound of Formula (I) to Formula (V) and to convert the compound of Formula (III) to Formula (IV);
- and
- wherein the compounds of Formulas (I), (II), (III), (IV), and (V) are optionally in the form of a pharmaceutically acceptable salt.
18 more elements
Dependencies are inferred from the claim text.